DHR
Danaher Corporation
$202.55
▲ 1.3%Updated Aug 7, 11:30 AM ET
DHR at a glance — five pillars scored 0–100 from real filed financials.
Overall: Neutral · 48/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▼ Down 8.9% over the last 12 months
Market Cap
$140.09B
P/E
38.92x
Forward P/E (est.)
38.79x
ROE
7.1%
Revenue Growth
4.0%
EPS Growth
0.3%
Profit Margin
14.9%
FCF Yield
6.0%
Debt / Equity
0.35x
ROIC
5.0%
Interest Coverage
16.4x
Current Ratio
1.87x
Dividend Yield
0.9%
Implied Growth (rev. DCF)
5.1%
Rating Score
48/100
Danaher Corporation (DHR) is a large-cap company in the Life Sciences Tools & Services industry, part of the Health Care sector of the S&P 500, with a market value around $140.09B.
In its latest reported year it generated about $24.57B in revenue and $3.61B in net profit.
Our model rates DHR Neutral (48/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Evidence of durable competitive advantage in the filed financials (9 years of history).
The filed history looks like a business competitors struggle to attack: high and steady margins, revenue that grows through cycles, and strong returns on capital.
59.1% average over the last 3 years
±2.2 pts around 58.0% across 9 years
grew in 6 of the last 8 year-over-year periods
positive in 9 of 9 years
5.0% latest fiscal year
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what DHR's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. DHR trades near $202.55, around its 50-day average ($178.68) and 200-day average ($203.99). Price tangled in its moving averages means there is no clear trend — the stock is ranging.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 72 it is overbought — the recent rally is stretched and can cool off.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. DHR's is $5.09 (~2.5% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month DHR found buyers near $174.22 (support) and sellers near $198.23 (resistance); its 52-week range is $160.93–$242.80. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.9× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
4Y CAGR
-0.2%
Revenue moved from $15.52B in 2017 to $24.57B in 2025, a 5.9% compound annual growth rate. The most recent year was roughly flat (4.0%) year over year. Slower, mature growth is common for established businesses.
Gross Margin
59.1%
Operating Margin
19.1%
Net Margin
14.7%
ROE
7.1%
Danaher Corporation keeps about 14.9% of each sales dollar as net profit, with a 59.1% gross margin and 19.1% operating margin. Return on equity is 7.1% and return on invested capital about 5.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$18.48B
Net Debt
$12.80B
Net Debt / EBITDA
2.73x
Debt / Equity
0.35x
Leverage: debt-to-equity is 0.4x, and operating profit covers interest about 16.4x, with a current ratio of 1.9x. That is a conservative balance sheet — a cushion in downturns. It carries roughly $18.48B of total debt against $5.69B of cash.
Operating CF
$6.42B
Free Cash Flow
$5.26B
FCF Margin
21.4%
In the latest year Danaher Corporation produced about $6.42B of operating cash flow and $5.26B of free cash flow after capital spending. That is a free-cash-flow yield of about 6.0% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
Can the payout survive a bad year? Scored from filed cash flow, earnings coverage, and the raise/cut record.
The dividend is being paid, but coverage or consistency is thinner than an income investor should rely on without a closer look.
Dividend yield
0.9%
Total paid (latest FY)
$878.00M
History on record
9 years
dividend uses 17% of free cash flow
24% of net income paid out
total dividends increased 1 year in a row
payout was cut at least once in the last 9 years
Coverage uses the latest fiscal year as filed with the SEC; the streak counts total dollars paid (per-share figures can carry split artifacts). Educational information, not income advice.
P/E
38.92x
P/S
5.23x
P/B
3.44x
EV / EBITDA
—
DHR trades at 38.9x trailing earnings (about 38.8x on estimated forward earnings), 5.2x sales, and 3.4x book value. Reverse-engineering today's price implies the market expects roughly 5.1% long-term free-cash-flow growth. That is a premium multiple that needs growth to justify it.
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
DCF fair value / share
$127.74
Current price
$202.55
Starting FCF (latest 10-K)
$5.26B
Growth, years 1–5
4.0%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Where DHR sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How DHR stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (324 S&P 500 companies), DHR ranks #49 of 324 by our overall rating. It trades at a premium versus the sector on earnings (38.9x P/E vs. 27.3x median) with a lower return on equity (7.1% vs. 14.1%) and slower revenue growth (4.0% vs. 7.6%).
P/E vs sector
38.9x
median 27.3x
ROE vs sector
7.1%
median 14.1%
Growth vs sector
4.0%
median 7.6%
Sector rank
#49
of 324 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 324 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $202.55 today · expected CAGR -6% – 5%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $25.55B | $26.57B | $27.64B | $28.74B | $29.89B |
| Net income | $3.83B | $3.99B | $4.15B | $4.31B | $4.48B |
| EPS | $5.54 | $5.76 | $5.99 | $6.23 | $6.48 |
| Share price (low) | $127.45 | $132.55 | $137.85 | $143.37 | $149.10 |
| Share price (high) | $216.12 | $224.76 | $233.75 | $243.10 | $252.83 |
| CAGR (low–high) | -37% / 7% | -19% / 5% | -12% / 5% | -8% / 5% | -6% / 5% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for DHR:
- Healthy free-cash-flow yield (~6.0%) funds buybacks and dividends.
- A conservative balance sheet (debt/equity 0.4x) lowers risk.
The case against DHR:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Valuation risk — at 38.9x earnings, disappointing results could compress the multiple.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Danaher Corporation is a large-cap health care business growing at a mature pace, with solid profitability, and a sound balance sheet. It trades at 38.9x earnings, which our model scores Neutral (48/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 32 Wall Street analysts covering DHR recommend (August 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Latest SEC Filings
DHR's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
In the Idea Lab
DHR — frequently asked questions
Is DHR a good stock to buy?
We don't give buy or sell advice. Our model rates Danaher Corporation Neutral (48/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is DHR's rating on The Stocks School?
Danaher Corporation currently scores 48/100 (Neutral) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does DHR's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Danaher Corporation's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for DHR calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this DHR analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell DHR. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.